CELL INTELLIGENCE · 肿瘤细胞治疗研究

毛兰素介导的血管正常化解锁胶质母细胞瘤的 CAR-T 免疫治疗

Vascular normalization by erianin unleashes CAR-T immunotherapy in glioblastoma.

工程益生菌招募 CAR 巨噬细胞并建立免疫记忆，以清除小鼠体内的异质性胶质母细胞瘤

Engineered probiotics recruit CAR macrophages and establish immune memory to eradicate heterogeneous glioblastoma in mice.

CAR-T 疗法治疗中枢神经系统肿瘤的进展

Advances in CAR-T therapy for central nervous system tumors.

酸性靶向转换辅助的通用 CAR-T 细胞（ATT-CAR-T）疗法用于实体瘤治疗

Acidity-targeting transition-aided universal chimeric antigen receptor T-cell (ATT-CAR-T) therapy for the treatment of solid tumors.

胶质母细胞瘤的 CAR-T 细胞治疗：克服当前障碍与提升疗效的策略及其治疗意义

Chimeric antigen receptor T cell therapy for glioblastoma: overcoming current barriers and strategies to enhance efficacy for therapeutic implications

CAR-T 细胞：治疗脑肿瘤及其他疾病的工程化免疫细胞

CAR T cells: engineered immune cells to treat brain cancers and beyond.

肝细胞癌嵌合抗原受体（CAR）T 细胞治疗近期进展综述

A Review of Recent Advances in Chimeric Antigen Receptor (CAR) T-Cell Therapy for Hepatocellular Carcinoma.

EGFRVIII CAR-T 细胞治疗胶质母细胞瘤：早期 I 期临床试验（Second Affiliated）

Safety and Preliminary Efficacy of a Metabolically Armed Chimeric Antigen Receptor T Cell Therapy Targeting EGFRvIII for Recurrent Glioblastoma

这是一项早期 I 期注册临床试验，评估 CAR-T 细胞治疗胶质母细胞瘤的安全性、可行性及初步疗效。当前状态：尚未开始招募。计划入组 36 例。试验地点：中国 · 杭州（共 1 个中心，其中中国 1 个）。登记号：NCT07244666。

电穿孔（EP）介导的 DNA 疫苗在同种异体淋巴细胞增强下对已建立肿瘤模型的抗肿瘤疗效增强

Enhanced anti-tumor efficacy of electroporation (EP)-mediated DNA vaccine boosted by allogeneic lymphocytes in pre-established tumor models.

我们的临床前研究结果表明，通过过继转移接种过疫苗的健康供体来源的同种异体淋巴细胞来增强 EP 介导的 DNA 疫苗接种，可提高抗肿瘤疗效。

表达 IL-15/IL-18 和 CXCR2 改善 EGFRvIII 靶向 CAR-T 细胞在乳腺癌中的浸润与存活

Expressing IL-15/IL-18 and CXCR2 improve infiltration and survival of EGFRvIII-targeting CAR-T cells in breast cancer.